obstructive hypertrophic cardiomyopathy

BMS buys Asian rights to key growth drug Camzyos
BMS buys Asian rights to key growth drug Camzyos
Pharmaphorum
Bristol Myers Squibb
Asia
Camzyos
obstructive hypertrophic cardiomyopathy
Flag link:
Bristol Myers wins FDA approval for first drug to treat inherited heart condition
Bristol Myers wins FDA approval for first drug to treat inherited heart condition
BioPharma Dive
Bristol Myers Squibb
Camzyos
obstructive hypertrophic cardiomyopathy
FDA
Flag link:
BMS Presents Robust Mavacamten Results in HCM Ahead of FDA Decision
BMS Presents Robust Mavacamten Results in HCM Ahead of FDA Decision
BioSpace
Bristol Myers Squibb
FDA
clinical trials
mavacamten
obstructive hypertrophic cardiomyopathy
Flag link:
FDA delays its decision on Bristol Myers' $13B heart drug another three months
FDA delays its decision on Bristol Myers' $13B heart drug another three months
Endpoints
Bristol Myers Squibb
FDA
ICER
mavacamten
obstructive hypertrophic cardiomyopathy
Flag link:
Cytokinetics heart drug succeeds in mid-stage study, boosting shares
Cytokinetics heart drug succeeds in mid-stage study, boosting shares
BioPharma Dive
Cytokinetics
clinical trials
CK-274
obstructive hypertrophic cardiomyopathy
Flag link:
MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021
MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021
Xconomy
MyoKardia
clinical trials
mavacamten
obstructive hypertrophic cardiomyopathy
Flag link:
Safety qualms in MyoKardia mid-stage study cause investors to pause
Safety qualms in MyoKardia mid-stage study cause investors to pause
Endpoints
MyoKardia
obstructive hypertrophic cardiomyopathy
clinical trials
mavacamten
Flag link:
MyoKardia cuts all ties to Sanofi
MyoKardia cuts all ties to Sanofi
Biopharma Dive
MyoKardia
MYK-224
Sanofi
obstructive hypertrophic cardiomyopathy
mavacamten
Flag link:
Sanofi walks away from MyoKardia heart drug partnership, long before key data readout
Sanofi walks away from MyoKardia heart drug partnership, long before key data readout
Endpoints
Sanofi
MyoKardia
mavacamten
obstructive hypertrophic cardiomyopathy
Flag link: